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SURGICAL ETHICS CHALLENGES
When does conventional surgical therapy become
research?
James W. Jones, MD, PhD,a and Laurence B. McCullough, PhDb
A vascular surgeon arranges with operating room nurses
to alternate use of two Food and Drug Administration
(FDA)–approved and marketed endovascular prostheses
on odd and even operating days. This arrangement
requires which of the following?
A. No local review or patient consent, because both
devices are FDA-approved and marketed.
B. Institutional Review Board (IRB) approval and the
informed consent of patients.
C. Only the informed consent of participating patients.
D. IRB approval, but not the informed consent of patients.
E. IRB approval only if publication of results is intended.
The best response is B. The least acceptable response is A.
Some ethical constructs, particularly those involving informed
consent and the conduct of research, have been so uniformly
accepted as necessary to the rights of patients and the integrity
of scientific method that they have been codified into federal
law. Laws and medical ethics affecting research and patient
consent are not limited to “investigational” compounds and
devices. Although both devices proposed for use in our oper-
ating room scenario are approved for clinical care, the physi-
cian’s selection of the best product with which to address a
clinical problem should be based upon individual patient
assessment, specific indications, and anticipated outcomes.
When the selection process for a medication, graft, or implant
is randomized or preassigned, when the choice is not primarily
governed by the patient’s individual clinical characteristics, or
when the clinical outcome cannot be predicted, the procedure
must be considered clinical research rather than clinical care,
and the laws and ethical considerations applicable to research
become activated. The surgeon must modify his own behavior
accordingly and function in accordance with the legal and
ethical conventions that ensure integrity of scientific investi-
gation and the safety of research subjects.
The surgeon’s plan to alternate use of the first and
second endovascular devices is clearly intended to system-
atically collect data about the comparative performance of
the two prostheses rather than maximize the immediate
benefit to individual patients. The issue of which prosthesis
will provide the better clinical outcome is the open ques-
tion to be answered by application of scientific method and
statistical analysis of results. Choice A, proceeding with
neither the patient’s informed consent to participate in
research nor approval of a scientific protocol by the IRB, is
therefore not ethically or legally acceptable.
Choice C, proceeding with only the patient’s informed
consent, is appropriate to the conduct of routine clinical
care, but not clinical research. Although surgeons are per-
mitted wide latitude in developing innovative operative
techniques and typically function in a continuous quality
improvement mode,1 structured investigative plans require
the prior peer review of IRBs to evaluate the scientific
integrity of the study design and ensure satisfactory protec-
tion of human subjects. Similarly, Choice D, IRB approval
without the patient’s specific understanding and consent
that he is to participate in a scientific study, is not sufficient
to meet the legal and ethical requirements for the conduct
of research. In neither case is the requirement mitigated by
the FDA-approved status of the grafts to be used. There are
increasing concerns about the adequacy of the informed
consent process in addressing whether patients understand
that they are in a research rather than a therapeutic setting,
that their physician’s interest in adhering to the protocol
could conflict with his patient care interest, and that ran-
dom group assignment is not influenced by the individual
patient’s clinical indications.2 These potential misunder-
standings must be specifically addressed in the informed
consent procedure, particularly when such elements as
FDA approval and market status may confuse the layman’s
understanding of whether the procedure is or is not inves-
tigative and subject to the special rules governing clinical
research.
Choice E erroneously associates the definition of re-
search with publication or intent to publish. The results of
much research remain unpublished for any number of
reasons. Although patients have a legitimate concern that
their privacy be maintained when research results are pub-
lished, this is not the only risk to which they are subjected
when they participate in clinical research. IRB approval
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must be sought and received before initiation of the study
to ensure the soundness of the science and the safety of
patients. Subsequent decisions to publish or withhold the
study results have no bearing upon the potentially danger-
ous uncertainties of research which prior IRB review at-
tempts to minimize.
Choice B, obtaining each patient’s written informed
consent for participation in a study under the objective
oversight of the local IRB, satisfies legal and ethical require-
ments designed to promote safety, integrity, and scientific
merit in the conduct of clinical research.
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22ND ANNUAL WILLIAM J. VON LIEBIG FOUNDATION AWARD FOR EXCELLENCE IN VASCULAR
SURGICAL RESEARCH FOR RESIDENTS, FELLOWS, AND MENTORS—
FIRST PLACE: $5,000 (AUTHOR) AND $10,000 (SUPPORTING MENTOR)
Additionally, an unlimited number of $2,500 awards will be given for each manuscript achieving a score within the 1.0 to 2.0 range,
with $5,000 being awarded to each of their research mentors.
PURPOSE
• Motivate physicians early in their training to pursue their interest in research
• Recognize and support research professionals who supervise this critical function
ELIGIBILITY
• Author must be a Resident or Fellow on staff at an accredited vascular surgery program in the United States, Canada, or Mexico, with
senior collaborators acting in a consultative capacity.
• Manuscripts must be postmarked no later than September 3, 2002. Selection results will be conveyed to all applicants by October 31,
2002.
RESEARCH REQUIREMENTS
• The research may be experimental or clinical in nature, dealing with some fundamental or clinical aspect of vascular surgery. Both
basic and clinical research papers are especially encouraged.
• The manuscript must be an original, unpublished work (not submitted elsewhere for publication, except to the ACS Surgical Forum).
• The submission must be in English and include 1 copy of the typed manuscript and 1 original copy of illustrations (photographic
prints or original computer-generated images). The manuscript must also be submitted electronically in Microsoft Word or PDF
format on a PC computer disk or e-mailed to liebigfoundation@draxgroup.com. All submissions must comply with the Information
for Authors of the Journal of Vascular Surgery and include an abstract of 250 words or less.
• Accompanying each submission should also be the following: a cover letter from the Resident or Fellow indicating the manuscript
is to be considered for “The 22nd Annual William J. von Liebig Foundation Award for Residents, Fellows, and Mentors”; the
author’s full curriculum vitae; and a signed letter from the author’s mentor attesting that the author performed all the essential parts
of the experimental work reported.
SELECTION PROCESS
A select committee of vascular surgeons appointed by the Foundation will review the manuscripts submitted. 2002-2003
Committee Members include the following: Colleen M. Brophy, MD, Chairman; Elliot L. Chaikof, MD, PhD; Linda M. Graham, MD;
William H. Pearce, MD; Michael Sobel, MD; Jean A. Goggins, PhD, Secretary; and Thomas C. Naslund, MD, SAVS Ex-Officio.
The first-prize winner will be a guest of The von Liebig Foundation, and the award will be presented at the annual meeting of the
Southern Association for Vascular Surgery on January 15-18, 2003, at The Lowes Ventana Canyon Resort in Tucson, Arizona. Meeting
expenses incurred by the winning author will be reimbursed according to the travel policy of the Foundation. The winning manuscript
will be submitted to the Journal of Vascular Surgery or another publication of the author’s choosing for consideration for publication.
The William J. von Liebig Foundation reserves the right to withhold the granting of the award at the sole discretion of the Award
Committee, whose judgment with respect thereto shall be final and conclusive.
HISTORY
Since the award’s inception in 1982, 90% of previous award recipients have pursued careers in vascular or cardiothoracic surgical
research. Thirteen recipients have become Fellows of the American College of Surgeons, three are associate members of the College,
and one recipient is a Fellow of the American College of Cardiology. Two previous award winners are recipients of the von
Liebig–supported Mentored Clinical Scientist Development Awards, and approximately 50% have become successful peer review
funded researchers in vascular surgery. Past award winners include such well known researchers as Colleen Brophy, MD, Howard
Greisler, MD, Michael Marin, MD, and Kenneth Ouriel, MD.
CONCLUSION
It is the desire of the Foundation to encourage the movement of technical innovation and relevant clinical findings from the
laboratory to the vascular surgical community. It was Mr von Liebig’s hope that those who pursue this award and those who win it will
contribute to the advancement of medical care.
Further inquiries may be directed to the Foundation as follows:
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8889 Pelican Bay Blvd, Suite 403, Naples, Fla 34108
Telephone (239) 513-2229 Facsimile (239) 513-2239
www.vonliebigfoundation.com liebigfoundation@draxgroup.com
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